0001127602-24-012710.txt : 20240409
0001127602-24-012710.hdr.sgml : 20240409
20240409162525
ACCESSION NUMBER: 0001127602-24-012710
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240408
FILED AS OF DATE: 20240409
DATE AS OF CHANGE: 20240409
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Deschatelets Pascal
CENTRAL INDEX KEY: 0001657720
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 24833042
MAIL ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-04-08
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001657720
Deschatelets Pascal
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
Chief Scientific Officer
1
Common Stock
2024-04-08
4
M
0
69107
3.76
A
1185090
D
Common Stock
2024-04-08
4
S
0
64379
54.1165
D
1120711
D
Common Stock
2024-04-08
4
S
0
4728
54.9152
D
1115983
D
Stock Option (Right to Buy)
3.76
2024-04-08
4
M
0
69107
0
D
2026-02-07
Common Stock
69107
37280
D
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
This transaction was executed in multiple trades at prices ranging from $53.770 - $54.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $54.775 - $55.750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This stock option was granted on 02/08/2016 and is fully vested.
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
2024-04-09